Brokerages Set Acadia Healthcare Co. (ACHC) PT at $67.58
Shares of Acadia Healthcare Co. (NASDAQ:ACHC) have received a consensus recommendation of “Buy” from the sixteen brokerages that are presently covering the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $67.58.
Several equities research analysts have recently commented on the stock. Raymond James Financial Inc. raised shares of Acadia Healthcare from an “outperform” rating to a “strong-buy” rating and set a $65.00 target price for the company in a research report on Thursday, November 3rd. Mizuho cut their price target on shares of Acadia Healthcare from $71.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, November 3rd. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price target on shares of Acadia Healthcare in a report on Wednesday, November 2nd. TheStreet cut shares of Acadia Healthcare from a “buy” rating to a “hold” rating in a report on Wednesday, October 19th. Finally, RBC Capital Markets restated an “outperform” rating and set a $59.00 price target (down from $78.00) on shares of Acadia Healthcare in a report on Friday, October 21st.
Acadia Healthcare (NASDAQ:ACHC) opened at 38.34 on Tuesday. The company’s market capitalization is $3.35 billion. The stock’s 50 day moving average is $41.58 and its 200 day moving average is $51.39. Acadia Healthcare has a one year low of $34.40 and a one year high of $70.84.
Acadia Healthcare (NASDAQ:ACHC) last posted its earnings results on Tuesday, November 1st. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.61 by $0.03. The business had revenue of $789.40 million for the quarter, compared to the consensus estimate of $735.59 million. Acadia Healthcare had a return on equity of 8.91% and a net margin of 0.22%. The company’s revenue was up 53.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 earnings per share. On average, analysts anticipate that Acadia Healthcare will post $2.41 earnings per share for the current fiscal year.
In related news, major shareholder Waud Capital Partners Iii, L.L sold 457,443 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $48.39, for a total transaction of $22,135,666.77. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Reeve B. Waud sold 84,208 shares of the company’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $51.71, for a total transaction of $4,354,395.68. Following the sale, the director now directly owns 55,673 shares in the company, valued at approximately $2,878,850.83. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in Acadia Healthcare by 30.0% in the third quarter. Wells Fargo & Company MN now owns 6,857,782 shares of the company’s stock worth $339,803,000 after buying an additional 1,581,959 shares during the period. Pennant Capital Management LLC bought a new position in shares of Acadia Healthcare during the first quarter worth approximately $83,685,000. Price T Rowe Associates Inc. MD raised its position in shares of Acadia Healthcare by 11.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 10,958,149 shares of the company’s stock worth $542,976,000 after buying an additional 1,103,621 shares during the last quarter. American Century Companies Inc. bought a new position in shares of Acadia Healthcare during the second quarter worth approximately $56,657,000. Finally, JPMorgan Chase & Co. raised its position in shares of Acadia Healthcare by 20.2% in the third quarter. JPMorgan Chase & Co. now owns 6,008,192 shares of the company’s stock worth $297,706,000 after buying an additional 1,008,466 shares during the last quarter.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.
Receive News & Stock Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related stocks with our FREE daily email newsletter.